Revolution in a Blood Drop: New Test Unmasks Over a Dozen Cancers Early

Groundbreaking AI-powered blood test, CanScan®, detects over a dozen cancers from a single draw.
Published in prestigious Nature Medicine, validating its high accuracy and ability to pinpoint cancer's origin.
Received FDA Breakthrough Device Designation, promising a new era in early cancer screening.

In a stunning leap forward for oncology, Geneseeq has unveiled a game-changing weapon in the fight against cancer. The results, published on May 28, 2025, in the world-renowned journal Nature Medicine, detail the power of CanScan®—a revolutionary blood test capable of detecting more than a dozen cancer types, including elusive killers like pancreatic and ovarian cancer, often before symptoms arise^{1, 2, 5, 6, 8}.

This is not just another test; it's a paradigm shift. CanScan® harnesses the power of AI-driven whole-genome sequencing, meticulously analyzing subtle, cancer-specific signals in circulating cell-free DNA (cfDNA) from a single tube of blood^{1, 2}. By integrating fragmentomics, genomic, and epigenomic features, it doesn't just scream "cancer!"—it whispers where the threat lies, accurately predicting the tissue of origin (TOO) with remarkable specificity (99%)^{1, 5}.

The publication showcases interim findings from the JINLING cohort, part of the massive DECIPHE-Omnia Study involving over 8,000 participants, with the JINLING cohort now fully enrolled at 15,000⁶. This non-invasive marvel, which has already earned FDA Breakthrough Device Designation^{1, 2, 4}, offers a convenient, comprehensive alternative to often invasive, single-cancer screening methods, heralding a future where early detection is the norm, not the exception.

Revolution in a Blood Drop: New Test Unmasks Over a Dozen Cancers Early

References

Stay Updated!